Congenital insensitivity to pain-hyperhidrosis-absence of cutaneous sensory innervation

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
Feb 2010

Cayston: FDA approved

To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

Patient Assistance Programs1

Cayston

Gilead Sciences, Inc.

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Cayston

(aztreonam)Orphan drug

Gilead Sciences, Inc.

12.1 Mechanism of Action Aztreonam is an antibacterial drug [see Clinical Pharmacology (12.4) ] .

Approved Feb 2010FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Congenital insensitivity to pain-hyperhidrosis-absence of cutaneous sensory innervation.
Search all trials →
Search clinical trials for Congenital insensitivity to pain-hyperhidrosis-absence of cutaneous sensory innervation

Recent News & Research

No recent news articles indexed yet for Congenital insensitivity to pain-hyperhidrosis-absence of cutaneous sensory innervation.
Search PubMed for Congenital insensitivity to pain-hyperhidrosis-absence of cutaneous sensory innervation

Browse all Congenital insensitivity to pain-hyperhidrosis-absence of cutaneous sensory innervation news →

Specialist Network

No specialists currently listed for Congenital insensitivity to pain-hyperhidrosis-absence of cutaneous sensory innervation.

View all Congenital insensitivity to pain-hyperhidrosis-absence of cutaneous sensory innervation specialists →

Quick Actions